Pharmaceutical market access – The Netherlands
Strategic advice & project management
Get in touchWhat we do
Gaining access to innovative therapies such as ATMPs requires inventiveness. The reimbursement system does not always fit novel technologies. OAK Access thinks in solutions within and outside the box, with a broad stakeholder network.
OAK Access provides strategic advice to gain reimbursement for pharmaceutical innovations. Beyond procedures and dossiers, value demonstration, appropriate clinical use and payment models are central. A solid bottleneck and stakeholder analysis forms the foundation.
OAK Access coordinates all activities for market and patient access: central and decentral procedures, reimbursement dossiers, add-ons, financial negotiations with the ministry of health and Zorgverzekeraars Nederland, and reimbursement arrangements. If needed, we collaborate with experts in specific areas.
About OAK Access
OAK Access B.V. is an independent consultancy helping pharmaceutical and biotech companies make innovative treatments accessible for patients in the Netherlands. Ingrid van der Eijk combines twenty years of in-depth expertise with an extensive network across all key stakeholders.
Ingrid built her expertise at pharmaceutical and biotech companies, working across a broad range of therapies: from established medicines to oncology, cell and gene therapy (ATMPs), and treatments for serious rare genetic disorders. She has led both a Beneluxa assessment and an EUnetHTA Joint Clinical Assessment (JCA) from the industry side – processes requiring deep knowledge of European and national reimbursement procedures.
"How wonderful that new innovations keep emerging, giving patients hope, dreams and a better future. That motivates me every single day. It is precisely why I do everything in my power to make these treatments available in the Netherlands."
As a natural connector and team player, she quickly identifies solutions where others see barriers, always keeping the patient's best interest as her compass. Transparent, honest and results-driven: she delivers what she promises.
Clients & network
OAK Access works for national and international pharmaceutical and biotech companies seeking to make their treatments available in the Netherlands.
International pharmaceutical companies with broad portfolios, active across multiple indications and therapeutic areas.
Companies focused on rare diseases, cell and gene therapy (ATMPs) and other innovative treatments with specific reimbursement challenges.
International consultancies and HEOR parties requiring support for their clients on market access in the Netherlands.
Younger companies entering the Dutch market for the first time without in-house market access expertise.
Contact
Interested or have a question? Feel free to reach out. I will get back to you as soon as possible.